BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coyer L, Njoya O, Njouom R, Mossus T, Kowo MP, Essomba F, Boers A, Coutinho R, Ondoa P; HEP C-IMPACT Team. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project. Trop Med Int Health 2020;25:1098-109. [PMID: 32502290 DOI: 10.1111/tmi.13450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Razafindrazoto CI, Rasolonjatovo AS, Rabenjanahary TH, Randriamifidy NH, Rakotozafindrabe ALR, Razafimahefa SH, Ramanampamonjy RM. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country? Int J Infect Dis 2021;107:166-9. [PMID: 33895411 DOI: 10.1016/j.ijid.2021.04.061] [Reference Citation Analysis]
2 Gupta N, Manirambona L, Shumbusho F, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Camus G, Grant PM, Kateera F. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:542-51. [DOI: 10.1016/s2468-1253(21)00399-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]